Women's use of Rogaine Extra Strength not a health risk, FDA advisory committee says.
This article was originally published in The Tan Sheet
Executive Summary
ROGAINE EXTRA STRENGTH FOR MEN WILL ATTRACT FEMALE BUYERS in spite of proposed labeling that states that the anti-baldness treatment is "not for use by women," FDA's Nonprescription Drugs and Dermatologic & Ophthalmic Drugs Advisory Committees predicted at a July 16 joint meeting in Bethesda, Md. Sixteen committee members voted "yes" and two "no" to the question of whether a "substantial number of women" would disregard the label statement and purchase the 5% minoxidil product, which awaits OTC approval.
You may also be interested in...
Supplement GMP Warning Letters Make Modest Debut In 2010
Finalization of a settlement between the Federal Trade Commission and Rexall Sundown regarding unsupported cellulite treatment claims for the firm's Cellasene dietary supplement hinges upon approval of two related class action settlements pending in California and Florida, according to FTC
In Brief
Combe sells most of its OTC brands
People In Brief
Perrigo promotes in pricing, planning